Becker H, Federlin K
III. Medizinische Klinik und Poliklinik Justus-Liebig-Universität, Giessen, BRD.
Infusionsther Transfusionsmed. 1993 Apr;20 Suppl 1:118-20.
The use of immunosuppressive and long-acting antirheumatic drugs in the treatment of rheumatic diseases is often limited by their side effects. Therefore, it is urgent to search for drugs which are better tolerated and which are at least as effective. Several studies have been performed using intravenously administered immunoglobulins in rheumatoid arthritis patients and in small groups of patients suffering from other connective tissue diseases. The results demonstrate a rapid onset of clinical improvement in patients who respond to this treatment. The tolerance has been excellent so far. This therapy is immunomodulating, since it induces changes in B- and T-lymphocyte function, especially in immunoregulatory T-cell subpopulations. Future work should focus on the establishment of treatment schedules and on the definition of patient subgroups which might benefit most from intravenous immunoglobulin therapy.
免疫抑制药和长效抗风湿药在风湿性疾病治疗中的应用常因其副作用而受到限制。因此，迫切需要寻找耐受性更好且至少同样有效的药物。已经对类风湿关节炎患者以及一小部分患有其他结缔组织疾病的患者进行了几项使用静脉注射免疫球蛋白的研究。结果表明，对这种治疗有反应的患者临床改善迅速。到目前为止，耐受性良好。这种疗法具有免疫调节作用，因为它会引起B淋巴细胞和T淋巴细胞功能的变化，尤其是免疫调节性T细胞亚群的变化。未来的工作应集中在制定治疗方案以及确定可能从静脉注射免疫球蛋白治疗中获益最大的患者亚组。
